Cochrane Db Syst Rev
-
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primarily, to determine the effectiveness of a virtual reality (VR) intervention compared to an alternative or no intervention for people living with advanced cancer: on pain intensity, adverse events (AEs) and serious adverse events (SAEs); and secondarily, on additional pain properties (e.g. type, frequency), psychological well-being, other physical symptoms (e.g. anxiety) and quality of life. We will also report on the context in which the VR was implemented (setting, type and dose of VR).
-
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of vaccines to prevent Ebola virus disease in people who have been, or have potentially been, exposed to Ebola virus.
-
Cochrane Db Syst Rev · Nov 2024
Review Meta AnalysisPsychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.
Excessive daytime sleepiness is a common symptom of myotonic dystrophy. Psychostimulants are drugs that are increasingly used to treat hypersomnia in myotonic dystrophy. ⋯ In myotonic dystrophy, the effects of psychostimulants on excessive daytime sleepiness as assessed by the Maintenance of Wakefulness Test or Multiple Sleep Latency Test and on quality of life are very uncertain. Psychostimulants may improve hypersomnia as self-evaluated by the Epworth Sleepiness Scale and may increase the risk of adverse events. More randomised trials are needed to evaluate the efficacy and safety of psychostimulants in both the short and long term.
-
Perineal trauma after vaginal birth is common and can be associated with short- and long-term health problems. Perineal hyaluronidase (HAase) injection has been widely used to reduce perineal trauma, perineal pain and the need for episiotomy since the 1950s. The administration of HAase is considered to be a simple, low risk, low cost and effective way to decrease perineal trauma without causing adverse effects. ⋯ Perineal HAase injection during the second stage of labour may result in a lower incidence of perineal trauma (tears or episiotomy, or both) compared with no intervention, but not compared with placebo injection, in women having a vaginal delivery. Meanwhile, perineal HAase injection likely reduces the incidence of perineal oedema 24 hours after vaginal delivery compared with placebo injection. The potential use of perineal HAase injection as a method to reduce perineal trauma and perineal oedema remains to be determined as the number of high-quality trials and outcomes reported was too limited to draw conclusions on its effectiveness and safety. Further rigorous randomised controlled trials are required to evaluate the role of perineal HAase injection in vaginal deliveries, including evaluating whether there is any differential effect based on the dose, frequency and positioning of HAase injection.